title: Drug discovery and development in the field of cardiovascular disease. An interview with Dr William Greenlee by Alexandra Hemsley.
abstract: William Greenlee, the founder and president of MedChem Discovery Consulting LLC, has over three decades of research experience in industry at Merck Research Laboratories and the Schering-Plough Research Institute. He has contributed to the advancement of 20 drug candidates into preclinical development, 11 of which have progressed into clinical studies. Dr Greenlee was a member of the team that discovered the marketed drugs Vasotec™ and Prinivil™, and has led research teams that discovered several drug candidates that are now in clinical trials. His achievements and significant contributions to the field have been recognized with the presentation of a number of local and national awards, including the Alfred Burger Award in Medicinal Chemistry from the American Chemical Society and the Pennsylvania Drug Discovery Institute Drug Discovery Award. He was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame in 2006. Dr Greenlee was elected a Fellow of the American Association for the Advancement of Science in 2007 and an American Chemical Society Fellow in 2009.
authors.forename: William
authors.initials: W
authors.lastname: Greenlee
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001363:Awards and Prizes; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002626:Chemistry, Pharmaceutical; D017277:Drug Approval; D055808:Drug Discovery / Q000379:methods; D004345:Drug Industry; D015773:Enalaprilat / Q000627:therapeutic use; D006801:Humans
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015773:Enalaprilat